Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.53 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | P4HB | P07237 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386021 | 1.00 | MEN1 (0.54) | MEN1KMT2ACYSLTR2CYSLTR1MAOB | |
| SCHEMBL3334646 | 0.87 | KMT2A (0.67) | MEN1KMT2AMAOBPOLB | |
| SCHEMBL3334639 | 0.87 | KMT2A (0.67) | MEN1KMT2AMAOBPOLB | |
| SCHEMBL11452485 | 0.84 | KMT2A (0.65) | MEN1KMT2ACYSLTR2MAOBBCHE | |
| SCHEMBL30383113 | 0.84 | KMT2A (0.65) | MEN1KMT2ACYSLTR2MAOBBCHE | |
| SCHEMBL11452481 | 0.84 | KMT2A (0.65) | MEN1KMT2ACYSLTR2MAOBBCHE | |
| SCHEMBL25223392 | 0.80 | MAOB (0.76) | MEN1KMT2AMAOBBCHEALDH1A1 | |
| SCHEMBL30383304 | 0.80 | MAOB (0.76) | MEN1KMT2AMAOBBCHEALDH1A1 | |
| SCHEMBL11460533 | 0.80 | MAOB (0.76) | MEN1KMT2AMAOBBCHEALDH1A1 | |
| SCHEMBL10165676 | 0.80 | CYP1B1 (0.64) | MEN1KMT2AMAOBBCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | PIM1, PIM2, PIM3 | MEN1 3946/4885KMT2A 1421/4885CYSLTR2 4009/4885 |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK1A1, CSNK2A2 | MEN1 4294/4885KMT2A 686/4885CYSLTR2 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.